search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Pharmacokinetic study to assess the bioavailability of the cocoa flavanols catechin and epicatechin from different matrices.


- candidate number9302
- NTR NumberNTR2839
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR4-apr-2011
- Secondary IDs11-3-026 / DRUM11-CACA; MEC azM/UM / DRUM
- Public TitlePharmacokinetic study to assess the bioavailability of the cocoa flavanols catechin and epicatechin from different matrices.
- Scientific TitlePharmacokinetic study to assess the bioavailability of the cocoa flavanols catechin and epicatechin from different matrices.
- ACRONYMBioavailability of cocoa flevols from different matrices
- hypothesisTo assess the impact of the physical form of five different cocoa matrices on the bioavailability of the monomeric flavan-3-ols.
- Healt Condition(s) or Problem(s) studiedChocolate, Cocoa, Flavan-3-ols
- Inclusion criteria1. Adults between 20 and 45 years old;
2. Non-smoking individuals;
3. Capable and willing to sign the Informed Consent Form at voluntary basis;
4. Considered healthy based on their medical history and physical examination;
5. Female volunteers do not intend to become pregnant prior to or during the study and using adequate contraception.
- Exclusion criteria1. Clinically significant abnormal liver biochemistry;
2. Clinically significant abnormal serum creatinin;
3. Abnormal body mass index;
4. Use of concomitant medications or supplements.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupCrossover
- TypeSingle arm
- Studytypeintervention
- planned startdate 15-mei-2011
- planned closingdate15-jul-2011
- Target number of participants6
- InterventionsFive single doses of a cocoa products in randomised order with a minimal 5-day interval. Four of those cocoa products contain a high level of flavenols and are commercially available. One product is nog commercially available and is only made for clinical trials. This placebo product has exactly the same recipe as the other product, but uses the lowest level of flavenols as possible.
- Primary outcomeArea under the blood concentration - time curve (AUC).
- Secondary outcomeMaximal blood concentration (Cmax) and time to maximal blood concentration (Tmax).
- TimepointsBlood samples will be collected pre-dose and after 30, 60, 120, 240 and 360 min.
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESDr. F. Vanmolkot
- CONTACT for SCIENTIFIC QUERIESDr. F. Vanmolkot
- Sponsor/Initiator ProDigest BVBA
- Funding
(Source(s) of Monetary or Material Support)
Callebaut NV
- PublicationsN/A
- Brief summaryRationale:
Cocoa and chocolate products have generated significant interest due to their association with various health-protective and therapeutic activities, into a large extent related to the presence of high amounts of flavan-3-ols such as catechin and epicatechin. However, previous research has also shown that the final bioavailability and biological activity greatly depends on the physical form/matrix in which cocoa is ingested.

Objective:
The objective of the study is therefore to assess the impact of the physical form and matrix in which they are included, on the bioavailability of the monomeric flavan-3-ols catechin and epicatechin, following consumption of different cocoa formulations.

Study design:
Double-blinded, randomized, placebo-controlled cross-over study with 6 healthy volunteers. In this study, 5 specific cocoa formulations will be used.

Study population:
6 healthy, non-smoking adults between 20 and 45 years old.

Intervention:
The study will consist of five separate days with a minimal 5-day washout period in between. Each subject will consume each of the five products once in a crossover design, with a minimal 5-day washout period between samples. The order of the consumption will be randomized for each individual.

Main study parameter:
The aim of the study is to evaluate the effect of the physical form and the composition of cocoa matrices on monomeric flavan-3-ol bioavailability. Assessment and evaluation will be done by comparing the kinetics of the main study parameter: catechin and epicatechin in the serum following a single oral consumption of the cocoa formulation. To do this, blood samples will be collected pre-dose and after 30, 60, 120, 240 and 360 min.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
After an overnight fasting, a catheter is placed in the arm of each subject for repeated blood collection. Per study day, 6 times 16mL blood sample will be taken. The participants are to refrain from high flavan-3-ol containing products for a period starting 2 days prior to the start of each study day. The participants are asked not to change their normal dietary habits during the study period. No adverse effects are expected. Participants will not benefit directly from participation.
- Main changes (audit trail)
- RECORD4-apr-2011 - 12-sep-2012


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl